BioMarin Patient Finder Analysis

Executive Summary

BioMarin Pharmaceutical operates a portfolio of 10 approved rare disease therapies generating $3.22B in FY2025 revenue (+13% YoY). Following the $4.8B acquisition of Amicus Therapeutics (December 2025), BioMarin now owns two of the rare disease industry's largest undiagnosed patient populations:

Fabry disease: 69% underdiagnosis, ~20,200 US undiagnosed patients, 10-15 year diagnostic delays
Late-onset Pompe disease: 60% underdiagnosis, ~6,500 US undiagnosed patients, 7 year diagnostic delays

Combined Tier 1 Opportunity: $3.51M/year at 1% penetration, scaling to $17.54M at 5%

Portfolio Overview: Ada Patient Finder Opportunity by Drug

*Palynziq: Real opportunity is diagnosed but poorly controlled patients (~5,000-7,000), not truly undiagnosed due to universal newborn screening

Drug	Indication	Tier	Fit Score	Addressable Undiagnosed (USA)	Ada Revenue Opportunity (USA, 1%)
Galafold	Fabry Disease	Tier 1	9.5/10	10,000 patients	$2.34M/year
Pombiliti + Opfolda	Late-Onset Pompe	Tier 1	8.5/10	4,200 patients	$1.09M/year
Voxzogo	Achondroplasia	Tier 1	8.0/10	350 patients	$84,000/year
Brineura	CLN2 Disease (Batten)	Tier 2	6.5/10	22 patients	$10,700/year
Palynziq	PKU	Tier 3	4.5/10	190 patients*	$36,500/year
Vimizim	MPS IVA (Morquio A)	Tier 3	4.5/10	65 patients	$21,500/year
Aldurazyme	MPS I	Tier 3	5.0/10	29 patients	$5,600/year
Naglazyme	MPS VI	NO	3.5/10	33 patients	$7,200/year
Kuvan	PKU	NO	N/A	Generic competition; excluded
Roctavian	Hemophilia A	NO	N/A	Being divested; excluded

Galafold (migalastat) - Fabry Disease

▼

TIER 1 - PURSUE AGGRESSIVELY Fit Score: 9.5/10

FY2025 Revenue

$521.7M

+14% YoY

US Undiagnosed

20,200

69% underdiagnosis rate

Drug-Addressable

10,000

Amenable GLA variants (~50%)

Diagnostic Delay

10-15 years

Symptom onset to diagnosis

Market Opportunity

Market	Drug-Addressable Undiagnosed	Ada Opportunity (1%)	Ada Opportunity (5%)
USA	10,000 patients	$2.34M/year	$11.7M/year
DACH	1,560 patients	$324,500/year	$1.62M/year
Rest of World	4,750 patients	$855,000/year	$4.28M/year
COMBINED	16,310 patients	$3.52M/year	$17.6M/year

Symptom Profile for Ada

Early (Age 10-30): Burning pain in hands/feet (acroparesthesias) + inability to sweat/overheat (hypohidrosis) + GI issues (diarrhea, abdominal pain) + distinctive rash (angiokeratomas)

Later (Age 30-50): Above symptoms + cardiac (left ventricular hypertrophy) + renal failure (proteinuria → ESRD)

Ada Surface Ability: 9/10 - Highly distinctive symptom cluster in youth, 10-15 year delay confirms massive missed diagnosis window

Strategic Context

$4.8B acquisition of Amicus by BioMarin (December 2025)
Patent protection through 2037-2038 (generic entry blocked until Jan 30, 2037 via Teva settlement)
Only 2,730 patients treated globally vs. ~16,000 US+DACH+ROW addressable = 6x expansion potential
65% market share among amenable Fabry patients
Competitors: Fabrazyme/Replagal/Elfabrio (ERTs) hold ~68% total market share, but limited to ~50% of patients

Pitch Hook: Fabry disease affects 29,400 symptomatic Americans, yet 69% remain undiagnosed—20,200 patients experiencing burning pain, inability to sweat, and GI issues for an average of 10-15 years before diagnosis. BioMarin acquired Galafold for $4.8B (Dec 2025), treating only 2,730 patients globally while ~10,000 drug-addressable Americans with amenable GLA variants remain unfound. Ada can identify the distinctive pediatric/adolescent cluster, triggering genetic testing and capturing $234K annual revenue per patient—a $234M US addressable opportunity. This is BioMarin's largest undiagnosed patient pool and Ada's highest-value rare disease target.

Pombiliti + Opfolda - Late-Onset Pompe Disease

▼

TIER 1 - PURSUE AGGRESSIVELY Fit Score: 8.5/10

FY2025 Revenue

$599M

Run rate (4Q through Q3)

Growth Rate

+61.5%

YoY (9 months)

Drug-Addressable

4,200

US undiagnosed patients

Diagnostic Delay

7 years

Median (symptom to diagnosis)

Market Opportunity

Market	Drug-Addressable Undiagnosed	Ada Opportunity (1%)	Ada Opportunity (5%)
USA	4,200 patients	$1.09M/year	$5.46M/year
DACH	970 patients	$232,800/year	$1.16M/year
Rest of World	3,100 patients	$682,000/year	$3.41M/year
COMBINED	8,270 patients	$2.00M/year	$10.03M/year

Symptom Profile for Ada

Key Symptoms (Age 20-50): Progressive proximal muscle weakness (difficulty climbing stairs, rising from chairs, lifting arms overhead) + respiratory insufficiency (diaphragm weakness) + elevated CK (creatine kinase 300-3,000 U/L) + exercise intolerance

Ada Surface Ability: 8/10 - Distinctive symptom cluster; 7-year delay + 1% prevalence in undiagnosed neuromuscular cohorts = substantial opportunity

Key Finding: Studies show 1% of undiagnosed neuromuscular patients at tertiary centers have Pompe (Georgia example: 15 known cases vs. ~125 expected)

Strategic Context

Included in $4.8B Amicus acquisition (December 2025)
BioMarin guidance: $1B peak revenue potential
Superior efficacy vs Sanofi ERTs: 21m 6-min walk distance gain vs 7m for Lumizyme (PROPEL trial)
Real-world evidence: 50% of switchers show improved 6MWD or FVC
Phase 3 pediatric study ongoing (label expansion to <18 years)
Competitors: Sanofi Lumizyme/Nexviazyme dominate 89.75% of $2.04B Pompe market

Pitch Hook: Pompe disease affects 10,000 Americans with late-onset muscle weakness, yet diagnostic delays average 7 years—leaving 4,200+ undiagnosed as they're misdiagnosed with generic 'muscular dystrophy.' The symptom pattern is distinctive: proximal weakness (trouble climbing stairs, rising from chairs) plus respiratory insufficiency in 20-50 year-olds. Studies show 1% of undiagnosed neuromuscular patients at tertiary centers have Pompe. BioMarin acquired Pombiliti+Opfolda in a $4.8B deal (Dec 2025), and the combination therapy beat Sanofi's standard ERT by 3x in walking distance improvement. Ada can flag the proximal weakness + respiratory cluster, triggering enzyme testing and capturing $260K annual revenue per patient—a $109M US opportunity.

Voxzogo (vosoritide) - Achondroplasia

▼

TIER 1 - PURSUE AGGRESSIVELY Fit Score: 8.0/10 COMPETITIVE URGENCY: 2027

FY2025 Revenue

$900-950M

28% of total BioMarin revenue

Growth Rate

+26%

YoY (Q4: +31%)

Drug-Addressable

350

US undiagnosed (open growth plates)

Patent Expiry

2030

Core patents; orphan to Oct 2030

⚠️ Competitive Threat

BridgeBio infigratinib Phase 3 PROPEL3 (Feb 2026):

Superior efficacy: 2.10 cm/year height velocity vs 1.57 for Voxzogo
Oral formulation vs daily injection (major convenience advantage)
First statistically significant improvement in body proportionality in randomized trial
Timeline: Regulatory submissions H2 2026, approval likely 2027

Implication: Limited time to maximize Voxzogo penetration before superior oral competition arrives

Market Opportunity

Market	Drug-Addressable Undiagnosed	Ada Opportunity (1%)	Ada Opportunity (5%)
USA	350 patients	$84,000/year	$420,000/year
DACH	85 patients	$17,700/year	$88,500/year
Rest of World	3,500 patients	$630,000/year	$3.15M/year
COMBINED	3,935 patients	$731,700/year	$3.66M/year

Symptom Profile for Ada

Key Features: Disproportionate short stature (rhizomelic shortening) + macrocephaly (large head) + frontal bossing + midface hypoplasia + trident hand + lumbar lordosis + genu varum (bowed legs)

Ada Surface Ability: 7/10 - Most diagnosed at birth, but database evidence suggests underdiagnosis even for visible condition (2,435 identified in 205M individuals; milder cases delayed 1-3 years)

Strategic Context

BioMarin's #1 revenue product ($900-950M FY2025)
Treating patients in 55 countries (targeting 60+ by 2027), 73% international
Patent protection: Core patents 2030, orphan exclusivity Oct 20, 2030
BioMarin developing BMN 333 (next-gen long-acting CNP) as internal competition, Phase 2/3 starting H1 2026
Ascendis TransCon CNP also competitive threat (NDA filed March 2025)

Pitch Hook: Achondroplasia affects 14,500 Americans, yet database studies suggest underdiagnosis even for this visible condition—with ~350 pediatric patients eligible for Voxzogo remaining unidentified, particularly milder cases missed in early growth monitoring. With Voxzogo generating $927M and facing superior oral competition from BridgeBio by 2027 (2.10 cm/year growth vs 1.57 for Voxzogo in Phase 3), every early diagnosis matters. Ada's symptom checker can identify growth concerns, disproportionate limbs, and family history patterns to flag potential cases before growth plates close. Time-sensitive: Treatment window closes at growth plate closure, and competitive threat arrives 2027—making early patient identification critical to Voxzogo's remaining exclusivity window.

Brineura (cerliponase alfa) - CLN2 Disease (Batten)

▼

TIER 2 - PURSUE Fit Score: 6.5/10

FY2025 Revenue

~$180-200M

Estimated (not broken out)

Drug-Addressable

US undiagnosed patients

Label Expansion

2024

Children <3 years approved

Gene Therapy Threat

Post-2027

80-85% sales at risk by 2035

Market Opportunity

Market	Drug-Addressable Undiagnosed	Ada Opportunity (1%)	Ada Opportunity (5%)
USA	22 patients	$10,700/year	$53,500/year
DACH	6 patients	$3,200/year	$16,200/year
Rest of World	36 patients	$16,200/year	$81,000/year
COMBINED	64 patients	$30,100/year	$150,700/year

Symptom Profile for Ada

Key Cluster (Age 2-4): Seizures (often first symptom, refractory to anticonvulsants) + language delay/regression + developmental regression (lost previously acquired skills) + ataxia + myoclonus + vision loss

Ada Surface Ability: 8/10 - Specific symptom cluster at specific age window (2-4 years); mimics epilepsy/autism individually but combination distinctive

Critical Timing: Early treatment most effective (does NOT reverse existing neurological damage)

Strategic Context

Recent label expansion (July 2024) to children <3 years
Only approved therapy for CLN2 (first-mover advantage)
Gene therapy competition emerging: AAV therapies in development, 80-85% sales at risk by 2035
Ultra-rare population (~100 US patients total) limits scale
Biweekly intraventricular infusions (surgically implanted reservoir) = high treatment burden

Pitch Hook: CLN2 disease affects ~100 American children, yet diagnostic delays mean 22+ remain undiagnosed—often misdiagnosed as epilepsy or autism. Early symptoms (seizures + language regression at age 2-4) are distinctive but require high suspicion. With Brineura's recent expansion to infants (2024 label update) and gene therapy competition emerging by 2027, capturing patients early is critical—ERT is most effective when started before irreversible neurodegeneration. Ada's symptom checker can flag the specific CLN2 cluster (seizures + language regression in toddlers), triggering enzyme testing and capturing $486K annual revenue per child found before neurological damage progresses.

Tier 3 & Excluded Drugs (Summary)

Tier 3: Opportunistic

Drug	Indication	Key Issue	US Addressable
Palynziq	PKU	Universal newborn screening eliminates undiagnosed classic PKU; real opportunity is diagnosed but poorly controlled patients	190 undiagnosed (5,000-7,000 poorly controlled)
Vimizim	MPS IVA	Ultra-rare, mature product, declining strategic priority	65 undiagnosed
Aldurazyme	MPS I	Newborn screening (45+ states) reducing undiagnosed pool; Sanofi partnership limits BioMarin control	29 undiagnosed

Tier NO: Do Not Pursue

Drug	Indication	Reason for Exclusion
Naglazyme	MPS VI	Rarest disease in portfolio (~33 US undiagnosed), patent-expired, no strategic investment
Kuvan	PKU	Generic competition (patent expired 2024-2026), declining revenues
Roctavian	Hemophilia A	Being divested by BioMarin after commercial failure ($119M write-down)

Strategic Recommendations

1. Immediate Focus: Galafold & Pombiliti+Opfolda

Combined opportunity: $3.43M at 1% penetration, $17.16M at 5%

Massive undiagnosed pools: 10,000+ (Galafold) and 4,200+ (Pompe) US patients
Long diagnostic delays: 10-15 years (Galafold) and 7 years (Pompe)
$4.8B Amicus acquisition (Dec 2025) demonstrates extreme strategic priority
Distinctive symptom clusters identifiable by Ada

2. Symptom Checker Development Priority

Priority 1: Fabry

Age 10-30: Burning pain + hypohidrosis + GI + rash
Age 30-50: Above + cardiac/renal

Priority 2: Pompe

Age 20-50: Proximal weakness (stairs/chairs) + respiratory + elevated CK

Priority 3: Achondroplasia

Disproportionate short stature + skeletal features

Priority 4: CLN2

Age 2-4: Seizures + language regression

3. BioMarin Partnership Angle

Position Ada as the solution to unlock:

69% Fabry underdiagnosis (20,200 US patients)
60% Pompe underdiagnosis (6,500 US patients)
6x expansion potential for Galafold purely through diagnosis (2,730 treated globally vs 16,000 addressable)
Frame as "market expansion" (BioMarin's language), not patient recruitment

4. Competitive Urgency

Voxzogo: BridgeBio superior oral competition likely 2027; limited time to maximize penetration before growth plate closure AND competitive threat
Brineura: Gene therapy competition post-2027 (80-85% sales at risk by 2035); early treatment critical for efficacy

5. Economic Model & ROI

Scenario	Tier 1 Drugs (Galafold + Pompe + Voxzogo)	Galafold + Pompe Only
1% penetration	$3.51M/year	$3.43M/year
5% penetration	$17.54M/year	$17.16M/year

Break-even: <1% penetration on Tier 1 drugs | Payback: <12 months at 1% penetration